Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124291882 | 12429188 | 2 | F | 2011 | 20160627 | 20160602 | 20160705 | EXP | US-ASTRAZENECA-2016SE57412 | ASTRAZENECA | 55.00 | YR | F | Y | 64.60000 | KG | 20160706 | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
124291882 | 12429188 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | TWO TIMES A DAY | Y | U | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | |||||||
124291882 | 12429188 | 2 | SS | BYDUREON | EXENATIDE | 1 | Subcutaneous | FA0150 | 0 | 2 | MG | /wk | |||||||
124291882 | 12429188 | 3 | C | GLUCOPHAGE XR | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 1000 | MG | Q12H | ||||||||
124291882 | 12429188 | 4 | C | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 7-8 UNITS SUBCUTANEOUSLY BEFORE MEALS | 0 | ||||||||||
124291882 | 12429188 | 5 | C | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | 10 UNITS SUBCUTANEOUSLY BEFORE MEAL | 0 | ||||||||||
124291882 | 12429188 | 6 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | 0 | 13 | IU | QD | ||||||||
124291882 | 12429188 | 7 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | Oral | 0 | 50 | UG | QD | ||||||||
124291882 | 12429188 | 8 | C | VERAPAMIL ER | VERAPAMIL HYDROCHLORIDE | 1 | Oral | 180.0MG UNKNOWN | 0 | 180 | MG | ||||||||
124291882 | 12429188 | 9 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 20.0MG UNKNOWN | 0 | 20 | MG | ||||||||
124291882 | 12429188 | 10 | C | IMITREX | SUMATRIPTAN SUCCINATE | 1 | Subcutaneous | 6.0MG AS REQUIRED | 0 | 6 | MG | INJECTION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
124291882 | 12429188 | 1 | Diabetes mellitus |
124291882 | 12429188 | 2 | Diabetes mellitus |
124291882 | 12429188 | 3 | Diabetes mellitus |
124291882 | 12429188 | 4 | Diabetes mellitus |
124291882 | 12429188 | 5 | Diabetes mellitus |
124291882 | 12429188 | 6 | Diabetes mellitus |
124291882 | 12429188 | 7 | Thyroid disorder |
124291882 | 12429188 | 8 | Migraine prophylaxis |
124291882 | 12429188 | 9 | Blood cholesterol abnormal |
124291882 | 12429188 | 10 | Migraine |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
124291882 | 12429188 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
124291882 | 12429188 | Amnesia | |
124291882 | 12429188 | Appetite disorder | |
124291882 | 12429188 | Basal cell carcinoma | |
124291882 | 12429188 | Blood glucose fluctuation | |
124291882 | 12429188 | Drug dose omission | |
124291882 | 12429188 | Glycosylated haemoglobin increased | |
124291882 | 12429188 | Injection site extravasation | |
124291882 | 12429188 | Injection site mass | |
124291882 | 12429188 | Intentional product misuse | |
124291882 | 12429188 | Malignant melanoma | |
124291882 | 12429188 | Needle issue | |
124291882 | 12429188 | Pernicious anaemia | |
124291882 | 12429188 | Pustular psoriasis | |
124291882 | 12429188 | Squamous cell carcinoma |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
124291882 | 12429188 | 1 | 2010 | 2013 | 0 | |
124291882 | 12429188 | 2 | 20160205 | 0 | ||
124291882 | 12429188 | 5 | 20160524 | 20160524 | 0 | |
124291882 | 12429188 | 7 | 2008 | 0 | ||
124291882 | 12429188 | 8 | 2009 | 0 | ||
124291882 | 12429188 | 9 | 2006 | 0 |